Confo Therapeutics appoints Dr Christel Menet as Chief Scientific Officer
Brussels, Belgium: 10 May 2016 - Confo Therapeutics, an emerging drug discovery company, announced today that Dr Christel Menet is joining the company as Chief Scientific Officer, effective now. Dr Menet will lead the research activities and build Confo Therapeutics' pipeline of development programs targeting G protein-coupled receptors (GPCRs) that are currently considered undruggable for a wide range of conditions.
Dr Menet joins Confo Therapeutics from Galapagos, where she advanced through positions of increasing responsibilities, most recently as Director of Chemistry.
More info on Confo Therapeutics' website.
Next > FRX Polymers Inc and Shengyi Technology Co develop new low dielectric loss Copper Clad Laminate formulation for printed circuit boards
Previous > Nexstim Plc key technology patent granted for Europe